References
- Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. 2018. https://gco.iarc.fr/today.
- Culp MB, Soerjomataram I, Efstathiou JA, et al. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38–52. doi:https://doi.org/10.1016/j.eururo.2019.08.005.
- Lee DJ, Mallin K, Graves AJ, et al. Recent changes in prostate cancer screening practices and epidemiology. J Urol. 2017;198(6):1230–1240. doi:https://doi.org/10.1016/j.juro.2017.05.074.
- Zhou CK, Check DP, Lortet-Tieulent J, et al. Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int J Cancer. 2016;138(6):1388–1400. doi:https://doi.org/10.1002/ijc.29894.
- Kanto S, Ohyama C, Okada Y, et al. Clinical features of prostate cancer patients younger than 50 years: report of seven cases. Int J Urol. 2002;9(2):91–94. doi:https://doi.org/10.1046/j.1442-2042.2002.00427.x.
- Smith CV, Bauer JJ, Connelly RR, et al. Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research Multicenter prostate cancer database. J Urol. 2000;164(6):1964–1967. doi:https://doi.org/10.1016/s0022-5347(05)66929-7.
- Antunes AA, Leite KR, Dall’Oglio MF, et al. Prostate biopsy: Is age important for determining the pathological features in prostate cancer? Int Braz J Urol. 2005;31(4):331–337. doi:https://doi.org/10.1590/s1677-55382005000400006.
- Varkarakis J, Pinggera GM, Sebe P, et al. Radical retropubic prostatectomy in men younger than 45 years diagnosed during early prostate cancer detection program. Urology. 2004;63(2):337–341. doi:https://doi.org/10.1016/j.urology.2003.09.032.
- Salinas CA, Tsodikov A, Ishak-Howard M, et al. Prostate cancer in young men: an important clinical entity. Nat Rev Urol. 2014;11(6):317–323. doi:https://doi.org/10.1038/nrurol.2014.91.
- Thorstenson A, Garmo H, Adolfsson J, et al. Cancer specific mortality in men diagnosed with prostate cancer before age 50 years: a nationwide population based study. J Urol. 2017;197(1):61–66. doi:https://doi.org/10.1016/j.juro.2016.06.080.
- Fontanella P, Benecchi L, Grasso A, et al. Decision-making tools in prostate cancer: from risk grouping to nomograms. Minerva Urol Nefrol. 2017;69(6):556–566. doi:https://doi.org/10.23736/S0393-2249.17.02832-6.
- Zelic R, Garmo H, Zugna D, et al. Predicting prostate cancer death with different pretreatment risk stratification tools: a head-to-head comparison in a nationwide cohort study. Eur Urol. 2020;77(2):180–188. doi:https://doi.org/10.1016/j.eururo.2019.09.027.
- Clinckaert A, Devos G, Roussel E, et al. Risk stratification tools in prostate cancer, where do we stand? Transl Androl Urol. 2021;10(1):12–18. doi:https://doi.org/10.21037/tau-20-1211.
- Shariat SF, Karakiewicz PI, Suardi N, et al. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res. 2008;14(14):4400–4407. doi:https://doi.org/10.1158/1078-0432.CCR-07-4713.
- Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev. 1999;8(12):1117–1121.
- Hayat MJ, Howlader N, Reichman ME, et al. Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) program. Oncologist. 2007;12(1):20–37. doi:https://doi.org/10.1634/theoncologist.12-1-20.
- Huben R, Natarajan N, Pontes E, et al. Carcinoma of prostate in men less than fifty years old. Data from American College of Surgeons’ National Survey. Urology. 1982;20(6):585–588. doi:https://doi.org/10.1016/0090-4295(82)90304-1.
- Prendeville S, Nesbitt ME, Evans AJ, et al. Variant histology and clinicopathological features of prostate cancer in men younger than 50 years treated with radical prostatectomy. J Urol. 2017;198(1):79–85. doi:https://doi.org/10.1016/j.juro.2017.01.061.
- Bratt O, Berglund A, Adolfsson J, et al. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: A population-based study from the National Prostate Cancer Register of Sweden. Scand J Urol Nephrol. 2010;44(6):384–390. doi:https://doi.org/10.3109/00365599.2010.498793.
- Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005;173(6):1938–1942. doi:https://doi.org/10.1097/01.ju.0000158155.33890.e7.
- Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006;98(10):715–717. doi:https://doi.org/10.1093/jnci/djj190.
- Caulfield S, Menezes G, Marignol L, et al. Nomograms are key decision-making tools in prostate cancer radiation therapy. Urol Oncol. 2018;36(6):283–292. doi:https://doi.org/10.1016/j.urolonc.2018.03.017.
- Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53(1):68–80. doi:https://doi.org/10.1016/j.eururo.2007.09.002.
- Kim S, Karnes R, Nguyen P, et al. Clinical implementation of quality of life instruments and prediction tools for localized prostate cancer: Results from a National Survey of Radiation Oncologists and Urologists. J Urol. 2013;189(6):2092–2098. doi:https://doi.org/10.1016/j.juro.2012.11.174.
- Jiang WD, Yuan PC. Development and validation of prognostic nomograms for patients with metastatic prostate cancer. Int Urol Nephrol. 2019;51(10):1743–1753. doi:https://doi.org/10.1007/s11255-019-02224-z.
- Hou G, Zheng Y, Wei D, et al. Development and validation of a SEER-based prognostic nomogram for patients with bone metastatic prostate cancer. Medicine (Baltimore). 2019; 98(39):e17197 doi:https://doi.org/10.1097/MD.0000000000017197.
- Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317(24):2532–2542. doi:https://doi.org/10.1001/jama.2017.7248.
- Zhu X, Gou X, Zhou M. Nomograms predict survival advantages of gleason score 3 + 4 over 4 + 3 for prostate cancer: a SEER-based study. Front Oncol. 2019;9:646. doi:https://doi.org/10.3389/fonc.2019.00646.
- Siegel DA, O’Neil ME, Richards TB, Dowling NF, Weir HK. prostate cancer incidence and survival, by stage and race/ethnicity – United States, 2001–2017. MMWR Morb Mortal Wkly Rep. 2020;69(41):1473–1480. doi:https://doi.org/10.15585/mmwr.mm6941a1.
- Salmon C, Song L, Muir K, et al. Marital status and prostate cancer incidence: a pooled analysis of 12 case-control studies from the PRACTICAL consortium. Eur J Epidemiol. 2021;36(9):913–925. doi:https://doi.org/10.1007/s10654-021-00781-1.
- Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA Guideline. J Urol. 2013;190(2):419–426. doi:https://doi.org/10.1016/j.juro.2013.04.119.
- Kobayashi T, Kinoshita H, Nishizawa K, et al. Age-associated increase of prostate-specific antigen in a high level of men visiting urological clinics. Int J Urol. 2005;12(8):733–738. doi:https://doi.org/10.1111/j.1442-2042.2005.01121.x.
- Helpap B, Ringli D, Tonhauser J, et al. The significance of accurate determination of gleason score for therapeutic options and prognosis of prostate cancer. Pathol Oncol Res. 2016;22(2):349–356. doi:https://doi.org/10.1007/s12253-015-0013-x.